MX355580B - Anticuerpos humanos para ligando tipo factor de necrosis tumoral (tnf) humano 1a (tl1a). - Google Patents

Anticuerpos humanos para ligando tipo factor de necrosis tumoral (tnf) humano 1a (tl1a).

Info

Publication number
MX355580B
MX355580B MX2013005141A MX2013005141A MX355580B MX 355580 B MX355580 B MX 355580B MX 2013005141 A MX2013005141 A MX 2013005141A MX 2013005141 A MX2013005141 A MX 2013005141A MX 355580 B MX355580 B MX 355580B
Authority
MX
Mexico
Prior art keywords
human
ligand
diseases
disorders
tl1a
Prior art date
Application number
MX2013005141A
Other languages
English (en)
Other versions
MX2013005141A (es
Inventor
Skokos Dimitris
J Classon Brendan
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of MX2013005141A publication Critical patent/MX2013005141A/es
Publication of MX355580B publication Critical patent/MX355580B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invención se refiere a un anticuerpo humano aislado o un fragmento del mismo enlazado a antígeno que se enlaza específicamente y neutraliza actividad de ligando tipo TNF humano 1A (hTL1A), caracterizado porque comprende un par de secuencia HCVR/LCVR que se seleccionan del grupo que consiste de la SEC ID NO. 2/10, 18/26, 32/42, 50/58, 66/74, 82/90, 114/116, 118/26, 134/136, 138/146, 154/156, 158/166, 174/176, 178/186, 194/196, 198/206, 214/216, 218/226 y 234/236.
MX2013005141A 2010-11-08 2011-11-08 Anticuerpos humanos para ligando tipo factor de necrosis tumoral (tnf) humano 1a (tl1a). MX355580B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US41127610P 2010-11-08 2010-11-08
US201161478309P 2011-04-22 2011-04-22
PCT/US2011/059675 WO2012064682A1 (en) 2010-11-08 2011-11-08 Human antibodies to human tnf-like ligand 1a (tl1a)

Publications (2)

Publication Number Publication Date
MX2013005141A MX2013005141A (es) 2013-07-03
MX355580B true MX355580B (es) 2018-04-06

Family

ID=45002143

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013005141A MX355580B (es) 2010-11-08 2011-11-08 Anticuerpos humanos para ligando tipo factor de necrosis tumoral (tnf) humano 1a (tl1a).

Country Status (21)

Country Link
US (3) US8642741B2 (es)
EP (1) EP2638069B1 (es)
JP (2) JP6076911B2 (es)
KR (1) KR101896129B1 (es)
CN (1) CN103261228B (es)
AR (1) AR083785A1 (es)
AU (1) AU2011326097B2 (es)
BR (1) BR112013011245A2 (es)
CA (1) CA2816799C (es)
CL (1) CL2013001279A1 (es)
EA (1) EA030397B1 (es)
IL (1) IL226172A (es)
JO (1) JO3375B1 (es)
MX (1) MX355580B (es)
MY (1) MY185006A (es)
NZ (2) NZ610294A (es)
SG (2) SG190176A1 (es)
TW (1) TWI606118B (es)
UY (1) UY33715A (es)
WO (1) WO2012064682A1 (es)
ZA (1) ZA201304114B (es)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110229471A1 (en) 2008-11-26 2011-09-22 Cedars-Sinai Medical Center Methods of determining responsiveness to anti-tnf alpha therapy in inflammatory bowel disease
PT2564695E (pt) 2009-07-08 2015-06-03 Kymab Ltd Modelos animais e moléculas terapêuticas
US8766034B2 (en) 2010-09-22 2014-07-01 Cedars-Sinai Medical Center TL1A model of inflammation fibrosis and autoimmunity
JO3375B1 (ar) * 2010-11-08 2019-03-13 Regeneron Pharma أجسام مضادة بشرية للجين a1 الشبيه بعامل النخر الورمي (tl1a)
JP2014533930A (ja) 2011-09-19 2014-12-18 カイマブ・リミテッド 免疫グロブリン遺伝子多様性の操作およびマルチ抗体治療薬
EP3495389A1 (en) * 2011-09-30 2019-06-12 Teva Pharmaceuticals Australia Pty Ltd Antibodies against tl1a and uses thereof
US9253965B2 (en) 2012-03-28 2016-02-09 Kymab Limited Animal models and therapeutic molecules
US10251377B2 (en) 2012-03-28 2019-04-09 Kymab Limited Transgenic non-human vertebrate for the expression of class-switched, fully human, antibodies
GB2502127A (en) 2012-05-17 2013-11-20 Kymab Ltd Multivalent antibodies and in vivo methods for their production
WO2014078306A1 (en) 2012-11-13 2014-05-22 Regeneron Pharmaceuticals, Inc. Anti-prokineticin receptor (prokr) antibodies and uses thereof
CN105102067B (zh) * 2013-01-02 2020-03-03 艾科诺斯科技股份有限公司 结合tl1a的抗体及其用途
US9788534B2 (en) 2013-03-18 2017-10-17 Kymab Limited Animal models and therapeutic molecules
AU2014241162A1 (en) 2013-03-27 2015-10-22 Cedars-Sinai Medical Center Mitigation and reversal of fibrosis and inflammation by inhibition of TL1A function and related signaling pathways
US11707056B2 (en) 2013-05-02 2023-07-25 Kymab Limited Animals, repertoires and methods
US9783593B2 (en) 2013-05-02 2017-10-10 Kymab Limited Antibodies, variable domains and chains tailored for human use
US10208125B2 (en) * 2013-07-15 2019-02-19 University of Pittsburgh—of the Commonwealth System of Higher Education Anti-mucin 1 binding agents and uses thereof
US10316083B2 (en) 2013-07-19 2019-06-11 Cedars-Sinai Medical Center Signature of TL1A (TNFSF15) signaling pathway
CA2925723A1 (en) 2013-10-01 2015-04-09 Kymab Limited Animal models and therapeutic molecules
CA3056647A1 (en) 2013-11-13 2015-05-21 Robert ARCH Tumor necrosis factor-like ligand 1a specific antibodies and compositions and uses thereof
US10160805B2 (en) 2014-07-11 2018-12-25 New York University Methods of treating inflammatory bowel disease by administering tumor necrosis factor-like ligand 1A or an agonistic death-domain receptor 3 antibody
WO2016077720A1 (en) * 2014-11-14 2016-05-19 Protein One, Llc Binding agents and uses thereof
TWI703158B (zh) * 2015-09-18 2020-09-01 美商希佛隆公司 特異性結合tl1a之抗體
WO2017077715A1 (en) * 2015-11-02 2017-05-11 La Jolla Institute For Allergy & Immunology Method and medicament for treating airway and/or lung diseases
CR20180365A (es) * 2015-12-16 2018-09-28 Amgen Inc PROTEÍNAS DE UNIÓN AL ANTÍGENO BISPECÍFICO DE ANTI-TL1A/ANTI-TNF-a Y SUS USOS
CN109462996A (zh) * 2016-03-17 2019-03-12 西达-赛奈医疗中心 通过rnaset2诊断炎性肠病的方法
AU2017264578A1 (en) * 2016-05-09 2019-01-03 Bristol-Myers Squibb Company TL1A antibodies and uses thereof
MY191324A (en) 2016-10-26 2022-06-15 Cedars Sinai Medical Center Neutralizing anti-tl1a monoclonal antibodies
MX2019015304A (es) 2017-06-21 2020-02-17 Cephalon Inc Amortiguador de lavado para cromatografia de intercambio cationico.
MA52366A (fr) 2018-04-25 2021-03-03 Prometheus Biosciences Inc Anticorps anti-tl1a optimisés
RU2689522C1 (ru) * 2018-09-11 2019-05-28 Общество с ограниченной ответственностью "Пальмира Биофарма" Нуклеотидная последовательность, кодирующая слитый белок, состоящий из растворимого внеклеточного домена человеческого tnfr1 и константной части тяжёлой цепи человеческого igg4
CA3121162A1 (en) * 2018-11-29 2020-06-04 Cedars-Sinai Medical Center Rnaset2 compositions and methods of treatment therewith
AU2020371725A1 (en) 2019-10-24 2022-05-26 Cedars-Sinai Medical Center Humanized antibodies to TNF-like ligand 1A (TL1A) and uses thereof
CA3180632A1 (en) * 2020-06-03 2021-12-09 Cedars-Sinai Medical Center Methods and systems for measuring post-operative disease recurrence
EP4294443A1 (en) * 2021-02-18 2023-12-27 Prometheus Biosciences, Inc. Anti-tl1a antibody compositions and methods of treatment in the lung
EP4294444A1 (en) * 2021-02-18 2023-12-27 Prometheus Biosciences, Inc. Compositions comprising humanized antibodies to tnf-like ligand 1a (tl1a) and uses thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7820798B2 (en) 1994-11-07 2010-10-26 Human Genome Sciences, Inc. Tumor necrosis factor-gamma
US7597886B2 (en) 1994-11-07 2009-10-06 Human Genome Sciences, Inc. Tumor necrosis factor-gamma
US6927044B2 (en) 1998-09-25 2005-08-09 Regeneron Pharmaceuticals, Inc. IL-1 receptor based cytokine traps
AU783682B2 (en) * 1999-08-04 2005-11-24 Amgen, Inc. Fhm, a novel member of the TNF ligand supergene family
JP2005538682A (ja) * 2001-12-03 2005-12-22 アブジェニックス・インコーポレーテッド カルボキシックアンヒドラーゼｉｘ（ｃａｉｘ）腫瘍抗原に対する抗体
US20040101920A1 (en) 2002-11-01 2004-05-27 Czeslaw Radziejewski Modification assisted profiling (MAP) methodology
US20080233119A2 (en) * 2003-08-20 2008-09-25 University Of Miami Compositions and methods for treating inflammatory lung disease
US7850962B2 (en) 2004-04-20 2010-12-14 Genmab A/S Human monoclonal antibodies against CD20
US20090317388A1 (en) * 2005-05-25 2009-12-24 Linda Burkly Tl1a in treatment of disease
AU2006284922B2 (en) * 2005-08-30 2012-01-19 University Of Miami Immunomodulating tumor necrosis factor receptor 25 (TNFR25) agonists, antagonists and immunotoxins
MY159787A (en) 2006-06-02 2017-01-31 Regeneron Pharma High affinity antibodies to human il-6 receptor
US8119130B2 (en) * 2007-07-25 2012-02-21 Medimmune Limited Targeted binding agents directed to KDR and uses thereof—035
EA020886B1 (ru) 2007-11-13 2015-02-27 ТЕВА БИОФАРМАСЬЮТИКАЛЗ ЮЭсЭй, ИНК. Гуманизированные антитела против tl1a
JO3375B1 (ar) * 2010-11-08 2019-03-13 Regeneron Pharma أجسام مضادة بشرية للجين a1 الشبيه بعامل النخر الورمي (tl1a)

Also Published As

Publication number Publication date
JP2016220693A (ja) 2016-12-28
ZA201304114B (en) 2014-02-26
UY33715A (es) 2012-05-31
MX2013005141A (es) 2013-07-03
US9556277B2 (en) 2017-01-31
NZ706986A (en) 2016-04-29
MY185006A (en) 2021-04-30
CL2013001279A1 (es) 2014-03-07
CA2816799C (en) 2021-02-16
WO2012064682A1 (en) 2012-05-18
CN103261228B (zh) 2016-02-10
JO3375B1 (ar) 2019-03-13
TW201233796A (en) 2012-08-16
KR20130132842A (ko) 2013-12-05
SG190176A1 (en) 2013-06-28
US20120114654A1 (en) 2012-05-10
US8642741B2 (en) 2014-02-04
AR083785A1 (es) 2013-03-20
NZ610294A (en) 2015-06-26
BR112013011245A2 (pt) 2020-08-04
EP2638069B1 (en) 2018-01-03
JP6076911B2 (ja) 2017-02-08
SG10201504265RA (en) 2015-06-29
EP2638069A1 (en) 2013-09-18
JP6272970B2 (ja) 2018-01-31
CA2816799A1 (en) 2012-05-18
AU2011326097B2 (en) 2015-08-20
CN103261228A (zh) 2013-08-21
KR101896129B1 (ko) 2018-09-07
IL226172A (en) 2016-08-31
IL226172A0 (en) 2013-07-31
JP2014500014A (ja) 2014-01-09
EA030397B1 (ru) 2018-07-31
EA201370105A1 (ru) 2013-12-30
US20140120109A1 (en) 2014-05-01
US20170096491A1 (en) 2017-04-06
TWI606118B (zh) 2017-11-21
AU2011326097A1 (en) 2013-05-09

Similar Documents

Publication Publication Date Title
MX2013005141A (es) Anticuerpos humanos para ligando tipo factor de necrosis tumoral (tnf) humano 1a (tl1a).
EA201070596A1 (ru) Гуманизированные антитела против tl1a
JO3097B1 (ar) الأجسام المضادة c-Met
WO2011139974A3 (en) Anti-pai-1 antibodies and methods of use thereof
NZ610592A (en) Anti-il-23 antibodies
MX2014006158A (es) Metodos para el tratamiento de artritis psoriasica (psa) utilizando antagonistas de il-17 y alelos con respuesta o sin respuesta a la psa.
PE20080333A1 (es) Agentes para prevenir o tratar enfermedades inflamatorias
PH12015501994A1 (en) Antibodies that bind il-23
MX341958B (es) Anticuerpos contra el il33r humano y usos de los mismos.
IN2012DN03362A (es)
WO2008069999A3 (en) Anti-p-selectin antibodies and methods of using the same to treat inflammatory diseases
FI3172232T3 (fi) TREM-1-vasta-aineiden kohdennettu mutageneesi viskositeetin alentamista varten
NZ612175A (en) Anti ccr4 antibodies and uses thereof
NZ631543A (en) Antibodies to bradykinin b1 receptor ligands
Gertz et al. ANX005, an inhibitory antibody against C1q, blocks complement activation triggered by cold agglutinins in human disease
EA201101643A1 (ru) ВАРИАНТЫ ПРИМЕНЕНИЯ IL-1β АНТИТЕЛ И ИХ СВЯЗЫВАЮЩИХ ФРАГМЕНТОВ В СЕРДЕЧНО-СОСУДИСТОЙ СИСТЕМЕ
GB201109238D0 (en) Antibodies
WO2011159976A3 (en) Arthritis treatment
WO2015095863A3 (en) Alpha-enolase specific antibodies and method of use in immune diseases
MX2012011479A (es) Anticuerpos de interleucina-25 humanizados.
IN2012DN01981A (es)
IL213213A (en) Use of Human Monoclonal Antibodies or Antigen-Related Fragments Specific to Human Ligand Protein Protein in the Manufacture of Medicines to Prevent and / or Treat Pampigos
MX2018004039A (es) Anticuerpos humanos para ligando tipo factor de necrosis tumoral (tnf) humano 1a (tl1a).
MY176745A (en) Method of treating a tl1a-associated disease or disorder with human antibodies to tl1a
Luft et al. ATG and statins reduce incidence of severe chronic GVHD by distinct mechanisms involving CXCL9 and kynurenine catabolism

Legal Events

Date Code Title Description
FG Grant or registration